Article Text

OC-066 Gut specific regulatory t cells – a new frontier for crohn’s disease therapy
  1. R Goldberg1,2,3,
  2. C Scotta2,
  3. D Cooper4,
  4. P Irving1,
  5. J Sanderson1,
  6. N Shpigel5,
  7. F Marelli-Berg4,
  8. G Lombardi2,
  9. G Lord2,3
  1. 1Gastroenterology, Guy’s and St Thomas’ NHS Trust
  2. 2Medical Research Council Centre for Transplantation, King’s College London
  3. 3National Institute for Health Research Biomedical Research Centre, Guy’s and St Thomas’ NHS Trust
  4. 4William Harvey Research Institute, Bart’s and the London Queen Mary School of Medicine and Dentistry, London, UK
  5. 5Koret School of Veterinary Medicine, Hebrew University of Jerusalem, Rehovot, Israel


Introduction We have recently shown that Tregs isolated from the peripheral blood of patients with Crohn’s Disease (CD) can be expanded in vitro for therapeutic purposes. This is a critical step to developing cell based therapy for Crohn’s disease. The immune system used retinoic acid (ATRA) to induce a4b7 and thus prime Tregs to home to the gut. We sought use ATRA in-vitro in order to engineer gut specific Tregs for our Phase 1 trial in Crohn’s Disease. We then validated our findings in-vitro and in-vivo.

Method Tregs were isolated from peripheral blood of CD patients. ATRA supplementation was tested in standard culture conditions. The expression of a4b7 was assessed by flow cytometry. Suppression assays were performed using autologous effector T cells (Teff). An ibidi flow chamber system coated with recombinant human MAdCAM-1 was used for in-vitro trafficking experiments. SCID mice xenografted with foetal intestinal small bowel were used for in-vivoexperiments.

Results Ex-vivo expansion of Tregs in the presence of ATRA significantly induced the expression of a4b7 compared to Rapamycin alone (5.57%±3.12 vs 82.8%±9.5, p=0.0057) Cells treated with Rapa+ATRA maintained their superior suppressive ability compared to Rapamycin treated Tregs (95.8%±3.5% vs 91.15%±10.1% p=ns; at Treg:Teff 1:1 ratio). RAPA+ATRA Tregs did not produce IFNy or IL17 under pro-inflammatory cytokine challenge. When flowed through a MAdCAm-1 coated chamber, significantly higher numbers of Rapa+ATRA treated cells were observed to roll (Rapa 0.83±0.40 vs Rapa+ATRA 10.17±2.54 p=0.005), crawl (Rapa 0 vs Rapa+ATRA 4±0.89 p=0.001) and firmly adhere (Rapa 0.33±0.21 vs Rapa+ATRA 36.8±1.78, p<0.001) than those treated with Rapa alone. When Tregs were transferred into mice, a higher proportion of Tregs were found in xenografts of animals treated with Rapa+ATRA Tregs compared Rapa Tregs (12.10 (7.54–22.83) vs 4.97 (1.72–7.63), p=0.0056). Importantly there was a higher proportion of Tregs in inflamed xenografts of animals treated with Rapa+ATRA Tregs compared to those treated with Rapa Tregs (18.35 (12.95–28.63) vs 6.78 (2.65–9.61),p=0.0095).

Conclusion The addition of ATRA to Treg culture in-vitro confers a gut homing phenotype. This is functionally relevant in-vitro and in-vivo. The treatment maintains the highly suppressive and phenotypically stable phenotype of these cells. These gut specific Tregs will be implemented in our first in man trial Treg therapy for Crohn’s disease.

Disclosure of Interest None Declared

  • crohn’s disease
  • Immunology
  • novel therapeutics
  • regulatory t cell

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.